BlackRock, Inc. Increases Stake in BETA BIONICS INC

BlackRock, Inc. has filed a Schedule 13G with the SEC, disclosing an increased ownership in BETA BIONICS INC. As of the effective date of October 17, 2025, BlackRock, Inc. beneficially owns 2,778,764 shares of BETA BIONICS INC's common stock, representing 6.4% of the total outstanding shares. This marks a significant increase from previous holdings, with a value change of $44,828,193.32 and a shares change of 1,920,405. The filing indicates that BlackRock, Inc. has sole voting power over 2,735,187 shares and sole dispositive power over all 2,778,764 shares. The filing also notes that various persons have the right to receive dividends or proceeds from the sale of the common stock, but no single person's interest exceeds 5% of the total outstanding shares. The filing was signed by Spencer Fleming, Managing Director of BlackRock, Inc.